Cancer therapies can cause a variety of cardiac toxici es, including ischemia, cardiomyopathy, heart failure, myocardi s, arrhythmias, vascular disease, hypertension, and hyperlipidemia. Addressing cardiovascular risk at baseline, before ini a ng therapy, during cancer treatment, and in the survivorship period is impera ve. It may be useful to risk stra fy individuals with cardiovascular risk factors using biomarkers or imaging before they receive poten ally cardiotoxic therapies. Addionally, new guidelines recommend cardiac imaging with echocardiography in the survivorship period 6 to 12 months a er comple ng cancer therapy for these high-risk individuals. Close collabora on between cardiology and oncology in both clinical prac ce and future research is essen al. childhood cancer survivors with and without cardiomyopathy (cases and controls, respec vely) to iden fy whether individuals with single-nucleo de polymorphism in carni ne, remodeling, and alcohol reduc on pathways are predisposed to developing anthracycline cardiac toxicity. For those exposed to a high dose of anthracycline, the rs1786814 GG genotype (on the CELF4 gene) conferred a 10.2-fold risk of cardiomyopathy compared with a GA/AA genotype. 16 The re2232228 AA genotype in the hyaluronan synthase 3 gene conferred an 8.9-fold increased risk in cardiomyopathy compared with the GG genotype.
C ardiac imaging with echocardiography should be considered in the follow-up period in all survivors at high risk for cardiomyopathy. For the last 4 decades, oncologists have been aware that some cancer treatments, par cular chemotherapeu c agents and radia on, can result in cardiovascular complica ons, such as ischemic cardiovascular disease, cardiomyopathy, clinical heart failure, and arrhythmias. Although treatments op ons for pa ents with cancer have evolved with the introduc on of new targeted therapies, there con nues to be a growing apprecia on of the cardiac toxici es of cancer therapies-thus the emergence of a new fi eld of "cardio-oncology." [1] [2] [3] In parallel, there has been a rapid growth in the biologic understanding of cancer, molecular pathways, gene c suscep bility to cancer, and cancer syndromes as well as the toxici es of these therapies. 4 Here, we present an overview of the development of cardio-oncology, the cardiac toxicity of new an cancer agents, and newer techniques, such as imaging and biomarkers, that can be used for the monitoring and prevenon of cardiac complica ons of an cancer therapies.
CARDIAC TOXICITIES IN THE ERA OF PRECISION MEDICINE

Overview of Cardiovascular Toxici es of Current An cancer Therapies
A number of chemotherapeu c agents can cause cardiomyopathy and heart failure ( Table 1) . Perhaps best studied are the anthracyclines. First described in the 1970s by Lefrak and colleagues, 5 the incidence of anthryacycline-induced conges ve heart failure is dose dependent, with an es mated 2% at 200 mg/m 2 , 5% at 400 mg/m 2 , 16% at 500 mg/m 2 , and 26% at 550 mg/m 2 . 5 Other risk factors include female sex and extremes of age (aff ec ng both younger and older paents). 6 For those over the age of 65, there is a twofold increased risk of doxorubicin-induced conges ve heart failure compared with in those younger than 65 when adjus ng for a history of low/normal ejec on frac on, gender, history of cardiac disease, and performance status. 7 Similarly, in the Children's Oncology Group, the young seem par cularly at risk for cardiac toxicity; childhood cancer survivors are at a 15-fold higher risk of cardiomyopathy compared with agematched controls. [8] [9] [10] The dose-dependent rela onship of anthracyclines and heart failure in this pa ent popula on has also been well established, with an addi onal rising increase in those who also received chest radia on. 9 Some literature suggest that liposomal formula on may result in less cardiac toxicity. Skubitz et al 11 documented a case series in which individuals received more than 800 mg/m 2 without any evidence of cardiac dysfunc on. In ovarian cancer trials, it also seems that doses up to 550 mg/m 2 are safe from a cardiac perspec ve.
12 When administered at modifi ed doses of 45 mg/m 2 every 4 weeks, no cardiac toxicity has been observed. 13 More recently, researchers have tried to iden fy par cular gene c variants that could modify cardiomyopathy risk.
childhood cancer survivors with and without cardiomyopathy (cases and controls, respec vely) to iden fy whether individuals with single-nucleo de polymorphism in carni ne, remodeling, and alcohol reduc on pathways are predisposed to developing anthracycline cardiac toxicity. For those exposed to a high dose of anthracycline, the rs1786814 GG genotype (on the CELF4 gene) conferred a 10.2-fold risk of cardiomyopathy compared with a GA/AA genotype. 16 The re2232228 AA genotype in the hyaluronan synthase 3 gene conferred an 8.9-fold increased risk in cardiomyopathy compared with the GG genotype.
15 Subsequent models also suggest that par cular single-nucleo de polymorphisms are associated with cardiomyopathy, even in the se ng of lowdose anthracyclines. Carbonyl reductases catalyze reduc on of anthracyclines to cardiotoxic alcohol metabolites. For those with a polymorphism having the CBR3 V244M homozygous G genotype, exposure to low-dose anthracyclines at doses of 101-150 mg/m 2 had increased rates of anthracycline cardiomyopathy.
14 In one study of hematopoie c stem cell transplant recipients, a combined clinical and gene c heart failure model was be er at predic ng cardiomyopathy events compared with a purely clinical model.
18
Cardiac Toxici es in Cancer Survivors
Although many pa ents are at risk for developing acute cardiac toxici es during cancer therapies, it has become clear that both childhood cancer survivors and survivors of hematopoie c stem cell transplanta on have long-term cardiac risk. [19] [20] [21] Although o en related to anthracyclines and radia on, many survivors have an increase in the number of cardiac risk factors (diabetes, hypertension, hyperlipidemia, and overweight/obesity) compared with their age-matched controls. Recently, Armenian and colleagues 22 conducted a retrospec ve cohort study examining cardiac risk factors in adult cancer survivors (treated at older than 40) through the Kaiser Permanente system. With a median follow-up of 4.4 years of over 3.6 million individuals, cancer survivors had an increase in rates of hypertension, diabetes, hyperlipidemia, obesity, and tobacco use history compared with controls. Through mul variate regression, greater cardiovascular disease was seen in survivors of mul ple myeloma (incident rate ra o [IRR] of 1.70), lung cancer (IRR of 1.58), non-Hodgkin lymphoma (IRR of 1.41), ovarian cancer (IRR of 1.41), kidney cancer (IRR of 1.24), and breast cancer (IRR of 1.13) compared with noncancer controls. Addi onally, controls and cancer survivors with a history of cardiovascular disease had worsening overall 5-and 8-year survival.
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Overlapping Risk Factors in Cancer and Cardiac Disease
There is a growing body of evidence that suggests that cancer and cardiovascular disease share common risk factors, 23, 24 including tobacco use, 25 hypertension, 26 hyperlipidemia, 27 diabetes, 28 obesity, 29, 30 and sedentary behavior. 31, 32 Medica ons to help control diabetes and in turn, improve cardiovascular risk are currently in clinical trials as an cancer therapies 33 (NCT02360618, -02115464, and -02285855). Infl amma on also served as a risk factor for cardiovascular disease as well as malignancy. Although infec ons, like Helicobacter pylori and Epstein Barr virus, are associated with the development of lymphomas and leukemias, 34, 35 chronic infl ammatory condi ons, such as celiac sprue and systemic sclerosis, have higher rates of malignancy. 36, 37 Similarly, atherosclero c disease is characterized by infl amma on with endothelial cell adhesion, leukocyte recruitment, and accumula on of lipoproteins in the subendothelial space leading to an increase in monocytes and macrophages. 38, 39 In the results of the CANTOS trial, an inhibitor of interleukin-1B (IL-1B), a proinfl ammatory, showed reduc ons in cardiac events but also, a reduc on in new lung cancers (although the la er was not a predefi ned endpoint). 40, 41 More recently, another risk factor, clonal hematopoiesis, has emerged as a risk factor for hematologic malignancies and atherosclerosis. [42] [43] [44] [45] Human aging, known to be a risk factor for both cancer and cardiovascular disease, is associated with an increase in the frequency of soma c muta ons in hematopoie c cells, 45 including the epigene c modifi er enzyme Tet methylcytosine dioxygenase-2 (TET2), 43 an enzyme known to remove methyl groups from the DNA base cytosine. These soma c muta ons and TET2 defi ciency have a strong associa on with the development of blood cancers; they, however, are also associated with an increase in heart a acks and strokes. Fuster and colleagues 43 used a mouse model to study TET2 defi ciency in atherosclerosis-prone mice. Recons tu on with TET2-defi cient cells resulted in a marked increase in atherosclero c plaque size, sugges ng that TET2 muta ons in blood cells play a causal role in atherosclerosis.
New Emerging Therapies and Associated Cardiotoxicity
Be er delinea on of the molecular pathways responsible for tumorigenesis has led to targe ng these pathways for more eff ec ve treatment. For example, the observa on that kinases can become inappropriately ac ve in many cancer types has led to the development of kinases inhibitors for cancer treatment. 46 For example, about 20% to 30% of breast cancers overexpress HER2, a kinase receptor; trastuzumab, an an body targe ng HER2, has been eff ec ve for treatment of HER2-posi ve breast cancer. 47 However, in chronic myelogenous leukemia, the kinase ABL1 can become overac ve via a chromosomal transloca on (so-called "Philadelphia chromosome"). Small molecule inhibitors targe ng ABL1 kinase (the fi rst example being ima nib) have revolu onized treatment of chronic myelogenous leukemia. 48 In many cases, the kinases being targeted also play vital roles in cardiovascular homeostasis. 49 Therefore, targe ng these kinases can lead to cardiovascular sequalae resul ng in "on-target" toxicity. Small molecular inhibitors can also target mul ple kinases. In some cases, "off -target" ac vity of the kinase inhibitor can result in toxicity. Because kinases play diverse roles in cardiovascular biology, associated complica ons with the kinase inhibitor can result in heterogeneous toxici es, causing cardiomyopathy, arrhythmias, and vascular and metabolic dysregula on. 4 The fi rst example of cardiovascular toxicity with targeted therapies occurred with the use of trastuzumab for breast cancer. In the fi rst clinical trial, where trastuzumab was combined with standard chemotherapy regimen (including anthracyclines) for metasta c HER2-posi ve breast cancer, 27% of pa ents had evidence of cardiomyopathy, including both le ventricular dysfunc on and clinical heart failure (with 16% having grade 3 or higher events). 47 This prompted several strategies by the medical community, including tangen al treatment (where anthracyclines were given before trastuzumab) and cardiac monitoring during trastuzumab therapy, both of which signifi cantly lowered the rate of toxicity. 50 However, small molecular inhibitors approved for chronic myelogenous leukemia were associated with a number of diff erent toxici es, including pulmonary hypertension (with dasa nib), hyperglycemia and atherosclerosis (with nilo nib), and hypertension and vascular events (with pona nib). 51, 52 Another rapidly expanding class of kinase inhibitors that can lead to cardiovascular toxici es includes therapies that target VEGF, drugs that include bevacizumab (a monoclonal an body targe ng circula ng VEGF), or any number of small molecular inhibitors that target the VEGF receptors (examples include suni nib or pazopanib). 52 As a class, VEGF inhibitors are associated with hypertension, proteinuria, and (less frequently) cardiomyopathy and vascular events. Of these, hypertension is most common and seems to be an "on-target" toxicity that can occur in 25% to 87% of treated pa ents depending on the individual drugs. 52 Blood pressure increases o en occur early (within days of star ng the kinase inhibitor) and can decrease when treatment is withheld. There have been mul ple proposed mechanisms for how hypertension may occur. VEGF inhibi on may lead to impairment of nitric oxide bioavailability, increased endothelin-1 expression, and loss of capillaries ("capillary rarefac on"), leading to increased resistance across remaining vessels and renovascular hypertension. 53 More transla onal studies are needed to elucidate the specifi c contribu ons of each for individual therapy. The concomitant occurrence of proteinuria with hypertension in many VEGF inhibitortreated pa ents is reminiscent of pre-eclampsia and has implica ons for clinical care of these pa ents, of whom urine studies should be done along with blood pressure monitoring. 54 It is unclear which an hypertensive therapies are most effective for the treatment of VEGF inhibitorassociated hypertension; several groups have recommended the use of angiotensin-conver ng enzyme inhibitors and calcium channel blockers (such as amlodipine) as reasonable ini al regimen. 55 Given the rapid explosion of new kinase inhibitors approved for mul ple cancer types, new cardiovascular and metabolic complica ons can be seen. Ibru nib, a selec ve Adapted from Moslehi. 4 kinase inhibitor targe ng Bruton tyrosine kinase, has been approved for a number of B-cell malignancies but is associated with cardiac arrhythmias, including both atrial fi brilla on and ventricular arrhythmias. 56, 57 Ribociclib is a new CDK4/6 inhibitor that is approved for hormone-posi ve breast cancer that can lead to QT prolonga on and possible arrhythmias, thus requiring electrocardiographic monitoring on drug ini a on. 58 Mitogen-ac vated protein kinase inhibitors (such as trame nib), eff ec ve for treatment of a subset of melanomas, are associated with cardiomyopathy, requiring monitoring of cardiac func on. PI3K and mTOR inhibitors can lead to metabolic dysfunc on, such as hyperglycemia and hypertriglyceremia, which also require monitoring. 4, 52 Table 1 provides a list of a number of kinases inhibitors and observed eff ects on the cardiovascular system. Given the dearth of data, the precise preven ve and treatment strategies for each therapy are currently lacking.
In the case of "on-target" therapy, what is known regarding biologic ac vity of the specifi c kinase in the cardiovascular ac vity can help predict toxici es. Most commonly, however, cardiovascular sequalae of new therapies can introduce new biologic paradigms. For example, cardiomyopathy that can result with HER2 inhibitors has helped uncover a cri cal role for HER2 in cardiac homeostasis. 59 Basic studies suggest that HER2 is expressed in the heart and serves an important role in cardiac adapta on to stress. 60 The cardiovascular toxici es associated with VEGF inhibitors have helped uncover an important role for VEGF dysregula on in not only the cardio-oncology popula on but also, other pa ents. 49 VEGF dysregula on, for example, plays an important role in cardiovascular complicaons that occur during pregnancy, including pre-eclampsia and peripartum cardiomyopathy. 61, 62 In this regard, cardiooncology is o en regarded not merely as a new clinical fron er in medicine but also, as a new pla orm for basic and clinical inves ga on. 49 Cardiovascular toxici es with novel therapies extend beyond kinase inhibitors. The treatment of mul ple myeloma, for example, has been transformed by the introduc on of immunomodulatory drugs (such as thalidomide or lenalidomide) and proteasome inhibitors (such as bortezomib and carfi lzomib). 63 Both therapies represent new paradigms in cancer therapy, because the cellular protein degrada on machinery is targeted. Immunomodulatory drugs, for example, bind cereblon, a component of an E3 ubiqui n ligase, and promote ubiqui na on and proteasome-mediated degrada on of two key B-cell transcrip on factors. 64, 65 Immunomodulatory drugs have been associated with a number of cardiovascular toxic eff ects (Table 1) . Ini al clinical trials involving two immunomodulatory drugs, thalidomide and lenalidomide, showed a high risk of venous thromboembolic disease, especially in combina on with high-dose dexamethasone. Therefore, thromboprophylaxis with aspirin or an coagula on is recommended for most pa ents treated with immunomodulatory drugs, because they are also associated with an increased risk of arterial events, leading to a black box warning for increased risk of myocardial infarction and stroke. 66 However, carfilzomib, an irreversible proteasome inhibitor, has been associated with increased risk for various cardiovascular complica ons, including both arterial and venous thromboembolic events and hypertension. 67 These complica ons come in the backdrop of pa ents with mul ple myeloma who o en have cardiovascular comorbidi es and cardiovascular risk factors. 66 Finally, cancer immunotherapies have been transformave for the care of many pa ents with cancer and are rapidly being tested in new popula ons of pa ents with cancer. However, new cardiovascular sequalae are being seen with these therapies. Immune checkpoint inhibitors, for example, include both ipilimumab, an an -CTLA-4 an body, and anbodies targe ng the an -PD-1 or PD-L1. Examples of the la er include nivolumab and pembrolizumab. When used individually or in combina on therapy, these therapies have significantly enhanced antitumor activity and survival in cancer types (such as melanoma) that previously had few treatment op ons. These therapies can cause a mul tude of cardiovascular toxici es. 68 Specifi cally, rare cases of fulminant myocardi s have been reported soon a er ini al exposure to the therapies. 69, 70 Clinically, immune checkpoint inhibitorassociated myocardi s is characterized by early progressive and refractory cardiac electrical instability, myocardi s characterized by robust presence of T-cell and macrophage infi ltrates, and development of other autoimmune complica ons, such as myosi s and rhabdomyolysis. 69 Current data suggest that, although the incidence of myocardi s is infrequent (less than 1% with checkpoint inhibitor combina on therapy), it has high fatality rates when diagnosed (about 50% mortality). In addi on, the only risk factor that has been established is treatment with combina on therapy (for example, ipilimumab and nivolumab). 69 In the future, be er iden fi ca on of pa ents at risk for this severe drug side eff ect will be cri cal to ensure con nuous and successful use of the therapies.
Imaging Guidelines and Techniques for Monitoring and Preven ng Cardiac Toxicity
Cardiac imaging can have an important role in pretreatment risk assessment, early detec on of cardiac injury, and idenfi ca on of cardiac complica ons in pa ents receiving potenally cardiotoxic cancer treatment. Pretreatment risk assessment. Given that cardiomyopathy is a common toxicity of many of the current and emerging cancer therapies, there is a growing focus on iden fying pa ents at risk. Unfortunately, there are no established risk predic on models. Most clinicians use the presence of pre-exis ng cardiovascular disease or cardiovascular risk factors as markers of heightened risk for cardiotoxicity. 2 However, these factors individually have poor discrimina ve value. Pretreatment le ventricular size and cardiac func on also seem to iden fy pa ents at risk for treatment-related heart failure. 71 It is es mated that approximately 7.0% of the popula on has asymptoma c cardiac dysfunc on on screening. 72 Therefore, many cancer treatment clinical trials have required normal pretreatment cardiac func on as an inclusion criterion.
Assessment of cardiac func on can be performed using mul gated acquisi on scans, echocardiography, or cardiac MRI. Echocardiography is the preferred method because of the ability to provide comprehensive assessment of cardiac func on beyond le ventricular ejec on frac on (LVEF). The recent ASCO guidelines recommend pretreatment cardiac func on assessment with an echocardiogram along with a comprehensive clinical history and physical examina on in all pa ents before ini a on of poten ally cardiotoxic therapies. 73 This recommenda on is consistent with that of the American Society of Echocardiography and the European Society of Cardiovascular Imaging. 74 There has also been emerging interest in the use of more advanced cardiac imaging techniques, such as myocardial strain, for pretreatment risk assessment. Myocardial strain is a measure that could be obtained through echocardiography or cardiac MRI, and it is a measure of heart muscle deforma on. It can be considered to be a surrogate measure of myocardial contrac lity. Although strain can be measured in various direcons, the two measures that are closer to rou ne clinical applica on are global longitudinal strain (GLS) and global circumferen al strain (GCS). In the general cardiology literature, there is now a large body of evidence suppor ng the ability of myocardial strain to iden fy subclinical heart muscle abnormality that is not readily evident based on assessment of LVEF. Specifi cally in pa ents receiving anthracycline and/or trastuzumab therapy, pretreatment measure of GLS or GCS seems to diff erenate pa ents who are more likely to develop cardiotoxicity. [75] [76] [77] In one study, GLS greater than −17.5% (e.g., −16.0% or −12.5%) before anthracycline therapy was associated with a sixfold greater risk of heart failure or cardiac death in pa ents with hematologic malignancies. 77 Another study has suggested that GLS greater than −16.0% in anthracycline-treated paents with LVEF between 50% and 59% by echocardiography was associated with a 4.7-fold higher risk of major adverse cardiac events. 76 No such thresholds are currently available for GCS. Whether interven ons based on baseline strain or LVEF abnormali es alter overall outcomes remains to be determined. However, in pa ents who are felt to be at elevated risk for cardiac toxicity based on abnormal or low-normal cardiac function, multiple cardiovascular risk factors, or prior cardiac history, cardiology assessment and risk factor op miza on may be appropriate. Detection of cardiotoxicity during treatment. Because iden fying pa ents at risk for cardiotoxicity before cancer treatment is challenging, there is a necessity to screen for cardiotoxicity during cancer treatment. Clinical assessment itself is inadequate, because most pa ents develop asymptoma c cardiac dysfunc on. Much of the literature on idenfying asymptoma c cardiac dysfunc on has focused on toxici es related to anthracyclines and trastuzumab. Echocardiography provides the unique ability to iden fy both systolic and diastolic dysfunc on during treatment in a rapid fashion. The primary measure of cardiotoxicity used in clinical trials and prac ce is a threshold reduc on in LVEF during treatment. Although this threshold has not been inconsistent in the literature, the most common defi ni on is a greater than 10% reduc on in LVEF to a value below the lower limit of normal for the laboratory and the imaging modality.
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Among cardiac imaging techniques, three-dimensional echocardiography provides a reproducible measurement of changes in LVEF and has been endorsed in societal expert consensus statements. 2, 73, 74 However, LVEF as a sole marker of cardiotoxicity, especially with anthracyclines, seems to be insuffi cient. Large prospec ve studies have shown that, a er a reduc on in LVEF occurs, only approximately 20% of pa ents will have complete recovery of cardiac func on, despite appropriate heart failure treatment. 78 Therefore, there is a growing interest in more precise and earlier detec on of myocardial changes with cancer treatment. Myocardial strain imaging and serum biomarkers have been the forerunners for this role.
The strength of strain imaging is in its robust reproducibility when using vendor-specifi c analy c algorithms. 79 With sequenal strain analysis, changes in myocardial GLS and GCS seem to precede threshold changes in LVEF used to defi ne cardiotoxicity. The American Society of Echocardiography and European Associa on of Cardiovascular Imaging (ASE/EACVI) posi on statement has suggested using a rela ve reduc on in GLS by more than 15% to defi ne subclinical cardiotoxicity (i.e., without a substan al reduc on in LVEF). 80 Such a change should prompt considera on of cardiology consulta on. It should be noted that the clinical signifi cance of reduc on in GLS is not clear. In addi on, whether cardiac interven ons for isolated reduc on in GLS improve long-term cardiovascular outcomes in pa ents receiving cancer therapy is not known. This ques on is, however, the subject of an ongoing randomized, controlled trial (the SUCCOUR trial, ACTRN 12614000341628). Other echocardiographic measures, such as mitral annular systolic and diastolic veloci es and diastolic func on, have been assessed as early markers of myocardial injury but have not shown robust associa on with cardiotoxicity.
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Screening of cancer survivors. A greater spectrum of cardiovascular disease is seen in survivors, such as cardiomyopathy, cerebrovascular disease, arrhythmias, and radia on-related changes, like pericardial constric on, valvular stenosis and regurgita on, and coronary artery disease. In pediatric cancer survivors, clear guidelines for the ming of cardiac screening have been established based on anthracycline dose, radia on exposure, and age at treatment 81 (www.survivorshipguidelines. org). However, such guidelines do not exist for adult cancer survivors. The recent ASCO guidelines suggest follow-up imaging 6-12 months a er comple on of cancer therapy in pa ents considered to be at elevated risk for heart failure (e.g., age older than 60, doxorubicin dose greater than or equal to 250 mg/m 2 , radia on therapy greater than or equal to 30 Gy with heart in the treatment fi eld, and mul ple cardiovascular risk factors). Similarly, the Na onal Cancer Center Network survivorship guidelines recommend an echocardiogram in pa ents with at least one cardiac risk factor. 82 The best method to iden fy subclinical cardiac dysfunc on in these adult survivors is not clear. In pediatric cancer survivors, cardiac MRI has been shown to be the most robust technique to identify reduced LVEF followed by threedimensional echocardiography. However, GLS and GCS measurements have been shown to iden fy a greater propor on of pa ents with myocardial abnormali es. The clinical signifi cance of these fi ndings and whether interven ons can alter the natural course of cardiac disease have not been established.
In pa ents receiving radia on therapy that may involve the heart in the treatment fi eld, the ASE/EACVI consensus statement recommends screening echocardiography and/or func onal tes ng for coronary artery disease 5 to 10 years a er exposure, regardless of symptoms. 83 Other imaging modali es, including cardiac CT and cardiac MRI, can have complementary roles in the diagnosis of pericardial disease when echocardiography is nondiagnos c. The use of coronary CT is an alternate method for detec on of coronary artery disease (CAD) with high sensi vity; however, its roune use in assessment of cancer therapy-related CAD is not established. Despite the enthusiasm for detec on, there is very li le in the way of reversing radia on-induced cardiovascular changes other than applica on of general principles of atherosclerosis management.
Given the growing body of literature of overlapping risk factors in cardiovascular disease and cancer (previously described) as well as the cardiac toxicity of many cancer therapies, all cancer survivors should have risk reduc on and lifestyle modifi ca ons addressed. Recently, an ABCDE approach has been proposed for cardiovascular health in pa ents with breast cancer and pa ents with prostate cancer 84, 85 (Sidebar 1).
Serum Biomarkers for Detec on and Preven on of Cardiotoxicity
Troponin I. Use of serum biomarkers to detect myocardial injury from cancer therapy is extremely a rac ve given that it is minimally invasive, is rela vely cheap, is easily interpretable, can be readily repeated, and has low measurement variability. Specifi cally in pa ents receiving anthracyclines with or without trastuzumab, mul ple serum biomarkers have been examined. Among these, marker-only eleva ons in Troponin I during anthracycline therapy have been consistently associated with subsequent cardiotoxicity 86, 87 In the older studies of pa ents receiving high-dose anthracycline therapy, eleva on in troponin with mul ple repeated measurements around the me of treatment was associated with subsequent cardiotoxicity. 87 However, single measurements also seem to have prognos c value. 86 Troponin I eleva ons have also been reported in pa ents receiving sequen al therapy with anthracyclines and trastuzumab. Eleva on in any one troponin measure when measured before and after every trastuzumab cycle was associated with subsequent trastuzumab-associated cardiotoxicity, lower propensity to recover with heart failure therapy, and adverse cardiac outcomes in follow-up. 88 Perhaps the most a rac ve use of troponins is to guide heart failure therapy. Although there are impressive data from a single study showing complete eradica on of cardiotoxicity in pa ents who were treated with angiotensin-conver ng enzyme inhibitor with early eleva on in troponin I during high-dose chemotherapy, this has not translated into rou ne prac ce. 89 Other studies have shown elevated troponin I in pa ents receiving small molecule tyrosine kinase inhibitors and an -VEGF therapy, but the overall data are limited. 90, 91 Addi onal research and data in this area are needed before adapta on of this testing in all pa ents is recommended. Other serum biomarkers. Other biomarkers that have been examined to identify early cardiac injury include B-type natriure c pep des (BNP), high-sensi vity C-reac ve protective, and myeloperoxidase to name a few. Similar to troponin eleva on, early eleva on in myeloperoxidase in pa ents receiving sequen al anthracycline and trastuzumab therapy was found to be predic ve of cardiotoxicity. 86 However, this biomarker has not been examined in other studies. BNP and NT-pro-BNP are other interesting biomarkers. Although eleva ons have been reported during anthracycline therapy, the predic ve value for cardiotoxicity or subsequent adverse cardiac outcomes has been inconsistent.
Serum biomarkers may have a role in other emerging therapies; however, studies with these other therapies are lacking. Case reports of cardiotoxicity, for example, with immune checkpoint inhibitors have not shown consistent associa on with eleva on troponin, even at the diagnosis of myocardi s.
Despite the enthusiasm and interest in the use of biomarkers for early detec on and interven ons to prevent heart • Dose of chemotherapy and radia on; pa ents and physicians should be aware of the total dose of certain chemotherapies (for example, anthracyclines) and radia on • E
• Exercise • Echocardiogram: per 2015 Na onal Comprehensive Cancer Network guidelines, consider echocardiogram in select pa ents within 1 year of comple on of anthracycline therapy failure, their use is limited by the inconsistent data on the types of assay to use, the ming of measurement, and the thresholds to defi ne toxicity or ini ate cardiac interven ons. However, the ASE/EACVI and the ASCO guidelines 2,73,74 do include troponin measurements as a method to follow for paents during cancer therapy; however, addi onal guidance on how this should be measured on acted on is not provided. Cardiac imaging and biomarkers in the era of precision medicine. Advanced cardiac imaging techniques and serum biomarkers are a rac ve methods to iden fy pa ents at risk for cardiotoxicity, which is defi ned as reduc on in LVEF or development of heart failure. Much of the enthusiasm in the fi eld has focused on iden fi ca on of early injury, with li le work on the use of these markers to off er interven ons that alter meaningful outcomes for pa ents with cancer. However, some such studies are currently ongoing. Ul mately, to move toward a precision medicine approach, clinical and genomics informa on along with imaging and serum biomarker data must be combined in a clinical risk predic on model that would provide the fl exibility to incorporate temporal changes in these measurements. This must be followed by studies that show that targeted interven ons can prevent the development of cardiovascular toxicity without altering cancer outcomes. Such work is eagerly awaited.
CONCLUSION
With rapidly growing understanding of the cardiac toxici es of cancer therapies, it is important to have a growing collabora on between cardiology and oncology. There seem to be related underlying mechanisms between these two diseases. Given the plethora of cardiac toxici es from new emerging targeted therapies, a general awareness of the cardiac risks of these medica ons is necessary. Finally, addi onal work con nues to be needed on the incorporaon of both imaging and blood biomarkers into oncology clinical trials to determine who would benefi t from these biomarkers and what interven ons should be performed in this se ng.
